• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Cytoreductive nephrectomy: a treatment of the past.减瘤性肾切除术：一种过去的治疗方法。
Can Urol Assoc J. 2010 Feb;4(1):68-9. doi: 10.5489/cuaj.779.
2
Cytoreductive nephrectomy in metastatic renal cell carcinoma.转移性肾细胞癌的减瘤性肾切除术
Curr Opin Urol. 2008 Sep;18(5):474-80. doi: 10.1097/MOU.0b013e32830a4f21.
3
Cytoreductive nephrectomy: does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything?细胞减灭性肾切除术：CARMENA（转移性肾细胞癌肾切除术和抗血管生成治疗）是否改变一切？
Curr Opin Urol. 2020 Jan;30(1):36-40. doi: 10.1097/MOU.0000000000000696.
4
Role of cytoreductive nephrectomy in renal cell carcinoma.细胞减灭性肾切除术在肾细胞癌中的作用。
Future Oncol. 2009 Aug;5(6):859-69. doi: 10.2217/fon.09.52.
5
The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.细胞减灭性肾切除术在转移性肾细胞癌中的不断演变的角色。
Curr Opin Urol. 2019 Sep;29(5):507-512. doi: 10.1097/MOU.0000000000000657.
6
Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study.腹腔镜减瘤性肾切除术作为全身应用白细胞介素-2治疗转移性肾细胞癌的术前准备：一项前瞻性研究。
Urology. 1999 Mar;53(3):496-501. doi: 10.1016/s0090-4295(98)00562-7.
7
Is cytoreductive nephrectomy relevant in the immunotherapy era?在免疫治疗时代，细胞减灭性肾切除术是否仍然相关？
Curr Opin Urol. 2019 Sep;29(5):526-530. doi: 10.1097/MOU.0000000000000659.
8
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.卡门娜真的应该改变我们对转移性肾细胞癌细胞减瘤性肾切除术的态度吗？一项系统评价和荟萃分析评估了靶向治疗时代的细胞减瘤性肾切除术。
Target Oncol. 2018 Dec;13(6):705-714. doi: 10.1007/s11523-018-0601-2.
9
Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.初始细胞减灭性肾切除术与初始靶向治疗转移性肾细胞癌的生存比较。
J Urol. 2018 Sep;200(3):528-534. doi: 10.1016/j.juro.2018.03.077. Epub 2018 Mar 21.
10
Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study.原发转移性肾细胞癌患者接受系统酪氨酸激酶抑制剂治疗中细胞减灭性肾切除术的影响：一项多中心回顾性研究。
Int J Urol. 2021 Apr;28(4):369-375. doi: 10.1111/iju.14466. Epub 2020 Dec 12.

引用本文的文献

1
Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.细胞减灭性肾切除术和转移性肾细胞癌：现状和未来展望。
Medicina (Kaunas). 2023 Apr 15;59(4):767. doi: 10.3390/medicina59040767.

本文引用的文献

1
A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment.一项基于人群的研究，考察酪氨酸激酶抑制剂对艾伯塔省转移性肾细胞癌患者生存率的影响以及治疗前肾切除术的作用。
Can Urol Assoc J. 2009 Aug;3(4):281-289. doi: 10.5489/cuaj.1121.
2
Sorafenib in advanced clear-cell renal-cell carcinoma.索拉非尼治疗晚期透明细胞肾细胞癌
N Engl J Med. 2007 Jan 11;356(2):125-34. doi: 10.1056/NEJMoa060655.
3
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.转移性肾癌患者的减瘤性肾切除术：一项联合分析
J Urol. 2004 Mar;171(3):1071-6. doi: 10.1097/01.ju.0000110610.61545.ae.
4
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.α干扰素作为晚期肾细胞癌新疗法临床试验的对照治疗。
J Clin Oncol. 2002 Jan 1;20(1):289-96. doi: 10.1200/JCO.2002.20.1.289.
5
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.肾切除术后联合干扰素α-2b与单独使用干扰素α-2b治疗转移性肾细胞癌的比较。
N Engl J Med. 2001 Dec 6;345(23):1655-9. doi: 10.1056/NEJMoa003013.
6
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.根治性肾切除术联合基于干扰素-α的免疫疗法与单纯干扰素-α治疗转移性肾细胞癌的随机对照试验
Lancet. 2001 Sep 22;358(9286):966-70. doi: 10.1016/s0140-6736(01)06103-7.
7
Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.接受生物反应调节剂治疗的转移性肾癌患者生存的预后因素。
J Urol. 1995 Jul;154(1):35-40.
8
Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.复发性或转移性肾细胞癌患者生存的预后因素
Cancer Res. 1988 Dec 15;48(24 Pt 1):7310-3.

Cytoreductive nephrectomy: a treatment of the past.

作者信息

Venner Peter

机构信息

Department of Medical Oncology, Cross Cancer Institute, Division of Medical Oncology, Department of Oncology, University of Alberta, Edmonton, AB.

出版信息

Can Urol Assoc J. 2010 Feb;4(1):68-9. doi: 10.5489/cuaj.779.

DOI:10.5489/cuaj.779
PMID:20165583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2812003/
Abstract
摘要